HCM
TCRT icon

Highbridge Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Highbridge Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-204
Closed -$164K – 1702
2016
Q4 		$164K Buy
+204
New +$184K ﹤0.01% 1159
2016
Q3 		– Sell
-1,185
Closed -$976K – 1676
2016
Q2 		$976K Buy
1,185
+851
+255% +$927K 0.02% 627
2016
Q1 		$372K Buy
+334
New +$342K 0.01% 1095
2015
Q4 		– Sell
-232
Closed -$313K – 1801
2015
Q3 		$313K Buy
+232
New +$383K ﹤0.01% 1214
2014
Q2 		– Sell
-101
Closed -$70K – 1288
2014
Q1 		$70K Buy
+101
New +$67.7K ﹤0.01% 999

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Highbridge Capital Management's TCRT Position: Q1 2017 in Review

Highbridge Capital Management sold out of Alaunos Therapeutics (TCRT) in Q1 2017, closing a stake of 204 shares — an estimated $164K sold.

Highbridge Capital Management first reported a position in TCRT in Q1 2014 and held it in 5 quarters. The position peaked at $976K in Q2 2016. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2017.

  • Highbridge Capital Management reported no remaining Alaunos Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 204 Alaunos Therapeutics shares in Q1 2017, an estimated $164K.
  • Highbridge Capital Management first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 5 quarters.
  • Highbridge Capital Management's Alaunos Therapeutics position peaked at $976K in Q2 2016.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.